Compass Therapeutics, Inc. (CMPX) 股票分析

公司概述

Compass Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to developing antibody-based therapeutics specifically for the treatment of oncology and various human diseases within the United States. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, a classification that signifies its reliance on research and development to create novel medical solutions rather than established commercial products. As of the latest data, the entity possesses a market capitalization of $981.48M and employs a workforce of 39 individuals. Although the annual revenue figure is listed as N/A due to the company's pre-commercial stage, the market cap of $981.48M indicates a significant valuation assigned by the market to its potential pipeline, particularly its lead product candidate tovecimig. This substantial valuation relative to the current employee count of 39 suggests that the market is pricing in significant future potential rather than current operational scale, which is typical for clinical-stage firms where success depends on future trial outcomes rather than existing sales volume.

财务健康

The company reports a net income of $-66,489,000 for the trailing twelve months, while its EBITDA stands at $-72,563,000, highlighting a substantial loss structure characteristic of early-stage biotechnology development. The gap between revenue, which is currently N/A, and the negative net income reveals an operational model where costs are driven almost entirely by research and development expenses rather than commercial overhead or cost of goods sold. Free cash flow is recorded at $-26,161,376, indicating that the company is burning through its capital reserves to fund its clinical programs and lacks the immediate cash generation required for self-sustaining operations. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, which is consistent with a revenue figure of N/A and underscores that the company has not yet reached a stage where it can derive profitability from sales. On the balance sheet, the company holds $208.91M in cash against $9.83M in debt, resulting in a debt-to-equity ratio of 5.00. Despite the high debt-to-equity figure, the vast excess of cash over debt suggests a conservative liquidity position regarding immediate solvency, as the company can fully service its obligations without needing to raise external capital immediately. The current ratio is exceptionally high at 15.02, indicating an abundance of current assets relative to current liabilities and providing a wide buffer against short-term financial pressures. However, the return on equity is -41.3% and the return on assets is -25.3%, metrics that reveal management is currently utilizing the company's capital base to generate negative returns, a standard but risky condition for clinical-stage entities awaiting regulatory approval and commercialization.

估值评估

The trailing P/E ratio is N/A due to the absence of earnings, while the forward P/E is listed as -11.30, a figure that implies the market is valuing the company based on projected negative earnings or a specific forward-looking model that accounts for anticipated dilution or losses. The price-to-book ratio stands at 4.94, indicating that the market is currently pricing the company at nearly five times its book value, which suggests a significant premium attached to the intellectual property and pipeline potential despite the lack of current profits. The price-to-sales ratio is N/A and the EV/EBITDA is -10.78; these alternative metrics further reflect the pre-revenue nature of the business where traditional valuation multiples are not applicable in a standard manner. The stock has traded within a 52-week range with a high of $6.88 and a low of $1.52, meaning the current valuation sits somewhere within this historical volatility band but does not necessarily indicate a specific entry point without current price data. The beta value is 1.30, which indicates that the stock price is expected to be 30% more volatile than the broader market, a characteristic often seen in small-cap biotechnology stocks that react sharply to clinical trial results or regulatory news.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated commercial sales to establish a growth trajectory. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue because no revenue base exists yet, and the focus remains entirely on clinical progression rather than commercial scaling. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the entity reinvests all available financial resources back into its research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is defined by a total reliance on capital markets for funding future growth, with no current income generation to support shareholder returns. This profile is typical for clinical-stage oncology companies where the primary objective is to advance the lead product tovecimig through clinical trials to eventually achieve market entry.